Sustained release of IL‐1Ra from biodegradable microspheres prolongs its IL‐1‐neutralizing effects

A sustained delivery system for interleukin-1 receptor antagonist (IL-1Ra) may have great therapeutic and industrial potential due to the cytokine activity as an IL-1 inhibitor. Here, we investigated the capability of biodegradable polymeric microspheres to sustain the release and prolong the therapeutic efficacy of IL-1Ra. IL-1Ra was encapsulated within rapidly degrading poly(lactic/glycolic acid) PLGA RG502H microspheres, which showed a desirable release profile of IL-1Ra in vitro. Pharmacokinetic study in mice revealed elevated serum levels of the recombinant IL-1Ra (rIL-1Ra) for up to 8 days following subcutaneous injection of IL-1Ra microspheres. In comparison, the serum levels of rIL-1Ra following subcutaneous or intravenous bolus injection of the soluble cytokine decreased very rapidly; within 48 h no recombinant cytokine was detected in mice sera. The sustained delivery of rIL-1Ra for over two weeks was efficient in inhibiting IL-1s-stimulated induction of serum IL-6. These results suggest that the present therapeutic protocol of daily bolus injections of the IL-1Ra may be replaced by a weekly injection of IL-1Ra within PLGA RG502H microspheres.

[1]  Martin Braddock,et al.  Targeting IL-1 in inflammatory disease: new opportunities for therapeutic intervention , 2004, Nature Reviews Drug Discovery.

[2]  Smadar Cohen,et al.  A continuous delivery system of IL‐1 receptor antagonist reduces angiogenesis and inhibits tumor development , 2004, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[3]  J. Frazier,et al.  Effects of Interleukin-1 Receptor Antagonist in a Slow-Release Hylan Vehicle on Rat Type II Collagen Arthritis , 1998, Pharmaceutical Research.

[4]  Robert Langer,et al.  Controlled Delivery Systems for Proteins Based on Poly(Lactic/Glycolic Acid) Microspheres , 1991, Pharmaceutical Research.

[5]  Y. Iwakura,et al.  IL-1 is required for tumor invasiveness and angiogenesis , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[6]  E. Voronov,et al.  Interleukin-1--a major pleiotropic cytokine in tumor-host interactions. , 2002, Seminars in cancer biology.

[7]  W. Arend.  The balance between IL-1 and IL-1Ra in disease. , 2002, Cytokine & growth factor reviews.

[8]  Z Domljan,et al.  Treatment of rheumatoid arthritis with recombinant human interleukin-1 receptor antagonist. , 1998, Arthritis and rheumatism.

[9]  Smadar Cohen,et al.  Characterization of PLGA microspheres for the controlled delivery of IL-1α for tumor immunotherapy , 1997 .

[10]  Gerhard Winter,et al.  Microencapsulation of rh-erythropoietin, using biodegradable poly(d,l-lactide-co-glycolide): protein stability and the effects of stabilizing excipients , 1997 .

[11]  J. Alcocer-Varela,et al.  Cytokine inhibitors in autoimmune disease. , 1996, Seminars in arthritis and rheumatism.

[12]  G. Campion,et al.  Dose-range and dose-frequency study of recombinant human interleukin-1 receptor antagonist in patients with rheumatoid arthritis. The IL-1Ra Arthritis Study Group. , 1996, Arthritis and rheumatism.

[13]  C. Dinarello,et al.  Biologic basis for interleukin-1 in disease. , 1996, Blood.

[14]  C. Dinarello,et al.  Interleukin 1 (IL-1)-dependent melanoma hepatic metastasis in vivo; increased endothelial adherence by IL-1-induced mannose receptors and growth factor production in vitro. , 1996, Journal of the National Cancer Institute.

[15]  Smadar Cohen,et al.  Controlled release of peptides and proteins from biodegradable polyester microspheres: an approach for treating infectious diseases and malignancies , 1995 .

[16]  S. Segal,et al.  Different regulatory levels are involved in the generation of hemopoietic cytokines (CSFs and IL-6) in fibroblasts stimulated by inflammatory products. , 1993, Cytokine.

[17]  J. Mier,et al.  Pharmacokinetics, safety and immunomodulatory effects of human recombinant interleukin-1 receptor antagonist in healthy humans. , 1992, Cytokine.

[18]  G. Pawelec,et al.  Determination of cytokines in synovial fluids: correlation with diagnosis and histomorphological characteristics of synovial tissue. , 1992, Annals of the rheumatic diseases.

[19]  B. Conti,et al.  Use of polylactic acid for the preparation of microparticulate drug delivery systems. , 1992, Journal of microencapsulation.

[20]  W. Arend.  Interleukin 1 receptor antagonist. A new member of the interleukin 1 family. , 1991, The Journal of clinical investigation.

[21]  D. Dripps,et al.  Interleukin-1 (IL-1) receptor antagonist binds to the 80-kDa IL-1 receptor but does not initiate IL-1 signal transduction. , 1991, The Journal of biological chemistry.

[22]  K. McIntyre,et al.  Inhibition of interleukin 1 (IL-1) binding and bioactivity in vitro and modulation of acute inflammation in vivo by IL-1 receptor antagonist and anti-IL-1 receptor monoclonal antibody , 1991, The Journal of experimental medicine.

[23]  R. Thompson,et al.  Biological properties of recombinant human monocyte-derived interleukin 1 receptor antagonist. , 1990, The Journal of clinical investigation.

[24]  J. Figueiredo,et al.  Renal filtration, transport, and metabolism of low-molecular-weight proteins: a review. , 1979, Kidney international.